It's been one year since NEA, in collaboration with four peer patient advocacy organizations, hosted the landmark patient-focused drug development (PFDD) meeting dedicated to eczema.
Published On: Dec 20, 2016
Last Updated On: Dec 20, 2016
On December 14, the U.S. Food and Drug Administration approved Eucrisa (crisaborole), a topical treatment for children and adults with mild to moderate atopic dermatitis (AD).
This marks the first new FDA-approved medication for atopic dermatitis in more than 10 years.
“It’s a big deal because for at least 15 years, other than reformulations of existing medications, there were no new treatments for atopic dermatitis,” said Dr. Lawrence Eichenfield, chief of pediatric and adolescent dermatology at UC San Diego School of Medicine. “The clinical trials have shown that crisaborole is effective at decreasing inflammation and is well-tolerated with long term use.”
Eucrisa works differently than other topical treatments on the market. It is not a steroid or a topical calcineurin inhibitor.
When applied to the skin, Eucrisa works on an enzyme called phosphodiesterase 4, or PDE4. PDE4 is produced by cells in our immune system and helps the body function in part by controlling cytokines. Cytokines are bits of protein also produced by our cells that contribute to inflammation. When cytokines are mistakenly triggered in the body, the resulting inflammation can contribute to the development of certain diseases, including atopic dermatitis.
In clinical trials, Eucrisa was shown to reduce symptoms of AD such as itching, redness, lichenification (thickened skin), weepy rash, and raw, scratched lesions. Overall, participants in the clinical trial achieved clear or almost clear skin after 28 days of use.
Eucrisa comes in a 2% topical ointment and is available by prescription for people ages 2 years old and up.
For more information visit Pfizer.com and talk to your doctor.